Literature DB >> 28321

Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney.

C E Odya, D V Marinkovic, K J Hammon, T A Stewart, E G Erdös.   

Abstract

Prolylcarboxypeptidase was purified from human kidney 1200-fold with 18% yield. The enzyme had no cathepsin A activity and appeared to be homogeneous in gel electrophoresis. The molecular weight of prolylcarboxypeptidase was estimated to be 115,000 by gel filtration. Under denaturing conditions the enzyme dissociated into subunits of 45,000 and 66,500 molecular weight. The enzyme cleaved benzyloxycarbonyl (Cbz)-Pro-Phe, representing the COOH-terminal end of angiotensin II and des-Asp1-angiotensin II (angiotensin III), at a rate of 31 micronmol/h/mg of protein. The rate of hydrolysis increased when phenylalanine in the N-protected dipeptide was replaced with alanine, valine, or leucine or when the octapeptide angiotensin II or the heptapeptide angiotensin III were the substrates. The enzyme also cleaved the angiotensin II antagonist saralasin (Sar1-Ala8-angiotensin II). The Km values were 1 mM, 2mM, and 0.77 mM with Cbz-Pro-Phe, angiotensin II, and angiotensin III, respectively. The enzyme had an acid pH optimum (4.5 to 5.5), but hydrolyzed angiotensin III at pH 7 at 50% of the optimal rate. Prolylcarboxypeptidase was inhibited by diisopropyl phosphorofluoridate and pepstatin, but not by sequestering agents or -SH reagents.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 28321

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

Review 1.  The plasma kallikrein-kinin system counterbalances the renin-angiotensin system.

Authors:  Alvin H Schmaier
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

2.  A vitellogenic-like carboxypeptidase expressed by human macrophages is localized in endoplasmic reticulum and membrane ruffles.

Authors:  James Harris; Nicole Schwinn; James A Mahoney; Hsi-Hsien Lin; Michael Shaw; Chris J Howard; Rosangela P da Silva; Siamon Gordon
Journal:  Int J Exp Pathol       Date:  2006-02       Impact factor: 1.925

Review 3.  Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function.

Authors:  Ervin G Erdös; Fulong Tan; Randal A Skidgel
Journal:  Hypertension       Date:  2010-01-11       Impact factor: 10.190

4.  Apelin is a positive regulator of ACE2 in failing hearts.

Authors:  Teruki Sato; Takashi Suzuki; Hiroyuki Watanabe; Ayumi Kadowaki; Akiyoshi Fukamizu; Peter P Liu; Akinori Kimura; Hiroshi Ito; Josef M Penninger; Yumiko Imai; Keiji Kuba
Journal:  J Clin Invest       Date:  2013-11-01       Impact factor: 14.808

Review 5.  The metabolic serine hydrolases and their functions in mammalian physiology and disease.

Authors:  Jonathan Z Long; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2011-06-23       Impact factor: 60.622

6.  Physiologic activities of the contact activation system.

Authors:  Alvin H Schmaier
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

7.  An exploration of bioactive peptides: My collaboration with Ervin G. Erdös.

Authors:  Rajko Igić
Journal:  J Biol Chem       Date:  2018-05-25       Impact factor: 5.157

8.  Prolylcarboxypeptidase (angiotensinase C) in human lung and cultured cells.

Authors:  K Kumamoto; T A Stewart; A R Johnson; E G Erdös
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

9.  Structural definition and substrate specificity of the S28 protease family: the crystal structure of human prolylcarboxypeptidase.

Authors:  Stephen M Soisson; Sangita B Patel; Pravien D Abeywickrema; Noel J Byrne; Ronald E Diehl; Dawn L Hall; Rachael E Ford; John C Reid; Keith W Rickert; Jennifer M Shipman; Sujata Sharma; Kevin J Lumb
Journal:  BMC Struct Biol       Date:  2010-06-11

10.  Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment.

Authors:  B Shariat-Madar; D Kolte; A Verlangieri; Z Shariat-Madar
Journal:  Diabetes Metab Syndr Obes       Date:  2010-04       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.